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Abstract Reverse transcriptase of human immunodeficiency
virus type 1 is a vitalenzyme in the HIV-1 replication cycle and
an attractive target of attempts to arrest a primary viral
infection. We designed a vector for eukaryotic expression of the
66 kDa subunit of reverse transcriptase under the control of the
immediate early cytomegalovirus promoter. Efficient transient
expression of the 66 kDa subunit of reverse transcriptase was
achieved in a variety of cells. Immunostaining of the transfected
cells revealed the cytoplasmatic localization of reverse tran-
scriptase. Reverse transcriptase activity was detected in all
transfected cell lines. Injection of this plasmid encoding the 66
kDa subunit of reverse transcriptase into mice resulted in strong
reverse transcriptase-specific immune responses indicating that
the 66 kDa subunit of reverse transcriptase is expressed in vivo.
Sera from DNA-immunized mice inhibited reverse transcription
in vitro.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
Reverse transcriptase (RT) of human immunode¢ciency vi-
rus type 1 (HIV-1) is a vital enzyme in the catalytic trans-
formation of viral RNA into double-stranded linear DNA
that is integrated into host cell chromosomes [1,2]. RT
presents an attractive target in attempts to arrest the HIV-1
replication not only by means of chemotherapy. Antibodies to
certain epitopes of RT inhibit its enzymatic activity [3,4]. A
high prevalence of these antibodies was associated with
asymptomatic infection and the inability to isolate virus
from the sera of HIV-1 positive individuals [5,6]. A potent
primary MHC class I-restricted CTL response was reported
against functional domains of RT [7]. If an immune response
directed against RT can interfere with the enzymatic activity
and a¡ect the virus viability, immunization against RT would
have a clear protective potential.
To address this problem and establish the vaccine potential
of RT, we constructed plasmid DNA for eukaryotic expres-
sion of the RT 66 kDA subunit (p66) that can form enzymati-
cally active homodimers [8]. The e⁄cient eukaryotic expres-
sion of enzymatically active p66 was achieved. The most
advanced way of antigen delivery at the moment appears to
be direct injection of antigen encoding DNA, i.e. genetic im-
munization [9^11]. In that case, antigens produced within the
cell are correctly expressed, folded and glycosylated by the
host. Our studies demonstrate that p66 encoding DNA directs
the e⁄cient expression of active enzyme in vivo and induces in
immunized mice immune responses with a clear protective
potential.
2. Materials and methods
2.1. Design of plasmid DNA encoding RT (pCMVRT)
The sequence encoding RT (HXB2) minus the His-tag and three C-
terminal amino acids was excized from pBRT5 [12] and ligated into
pSL1180 (Pharmacia, Sweden) at XhoI and XbaI sites of the poly-
linker in phase with the stop codon at the XbaI site. The resultant
plasmid was partially digested with EcoRV to generate a fragment
encoding RT with a restored stop codon £anked by EcoRV half sites
(5P terminal from pBRT5 and 3P terminal from the pSL1180 poly-
linker). The fragment was cloned into a vector plasmid with the pUC8
backbone under the control of the cytomegalovirus immediate early
promoter (CMV IE) promoter and the transcription termination sig-
nal from human papilloma virus type 16 [13] by cleaving the vector
with SalGI, ¢lling in the cohesive ends with the Klenow fragment of
DNA-polymerase, and digesting with HpaI. The RT gene insert was
con¢rmed by sequencing.
2.2. Expression of RT and preparation of cell lysates
Mouse ¢broblasts NIH3T3, human Burkitt lymphoma cells DG 75
and monkey COS cells were transfected with pCMVRT by electro-
poration or with lipofectamin (Gibco BRL, UK). Samples were with-
drawn after 24, 48 and 72 h and the expression of RT was analyzed by
SDS-PAGE with subsequent Western blotting, indirect immuno£uo-
rescent microscopy (IFL), quantitative indirect ELISA and a RT ac-
tivity assay. To assess the level of RT expression, cells were washed
with PBS, collected by centrifugation, resuspended (106 cells/ml) in the
lysis bu¡er containing 0.1 M Tris-HCl, pH 8.0, 0.15 M NaCl, 1 mM
EDTA, 2 mM PMSF and 1 mM Trasylol (Sigma, USA) and kept on
ice for 30 min. Nuclei were sedimented by centrifugation. Supernatant
samples were diluted 1:1 (v/v) with ice-cold stabilizing bu¡er contain-
ing 0.1 M Tris-HCl, pH 8.3, 0.2 M NaCl, 10 mM dithiotreitol, 2% v/v
Triton X-100 and 43.2% (v/v) glycerol and frozen at 370‡ to be
further assessed for RT activity.
2.3. Preparation of anti-RT rabbit polyclonal IgG
RT of HIV-1 was expressed in Escherichia coli and puri¢ed by
a⁄nity chromatography [14]. Two rabbits were immunized by injec-
tions of RT at weeks 0, 2, 4 and 17. Injections on weeks 0 and 2 were
done epidermal with 40 Wg of RT in PBS in complete and subsequent
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boosts intravenously with 15 Wg of RT in PBS in incomplete Freund
adjuvant. Blood was taken 12 days after the last boost. RT-speci¢c
IgG was prepared by ammonium sulfate precipitation and dialysed
against PBS. Control IgG was prepared from pre-immune rabbit
sera.
2.4. RT detection and quanti¢cation
2.4.1. Western blotting. Western blotting was performed with RT-
speci¢c rabbit IgG and peroxidase-conjugated goat anti-rabbit immu-
noglobulins (DAKO) using a ECL detection kit (Amersham) accord-
ing to the manufacturer’s instructions.
2.4.2. IFL. Cells were seeded on cover slips 24 and 48 h post
transfection and either ¢xed or grown for another 24 h. Suspension
cells were cytospinned onto object glasses before ¢xation. Non-trans-
fected cells and cells transfected with the vector plasmid [13] were
prepared similarly. Immunostaining was done with either rabbit
anti-RT IgG, or pre-immune rabbit IgG diluted in PBS containing
5% normal goat serum and 0.1% Triton X-100 as primary and swine
anti-rabbit FITC-conjugated IgG (DAKO, Denmark) as secondary
antibodies. Bisbenzimide (Hoechst 33258, 0.4 mg/ml) was added to
the secondary antibody for DNA staining.
2.4.3. Indirect quantitative assay of RT. To prepare a calibration
curve, known concentrations of RT (Boehringer Mannheim, Ger-
many) were coated in duplicates on 96 well ELISA plates (MaxiSorb,
Nunc, Denmark) in the concentration range 20 pg^200 ng per ml in
carbonate-bicarbonate bu¡er, pH 9.6. Lysates of transfected and
mock-transfected cells were coated in 2-fold dilutions up to 1:50.
Free binding sites on the plate were blocked by incubation with
PBS containing 5% BSA for 1 h at 37‡. An indirect ELISA was
performed as described earlier [15].
2.4.4. Assay of RT activity. Serial dilutions of the soluble fraction
of lysates of pCMVRT-transfected cells were assayed using the non-
radioactive RT kit (Boehringer Mannheim). The use of a substrate
solution with enhancer allowed the detection as low as 1 pg of RT per
well.
2.5. DNA Immunization
Three groups of C57B16 mice (eight each) were injected on days
1 and 26 with: (1) pCMVRT intra-muscularly (50 Wg), (2) pCMVRT
intra-epidermal (2 Wg), (3) vector DNA with no insert intra-muscu-
larly (50 Wg). Blood was taken 9^14 days after each injection. Sera was
analyzed by indirect ELISA. IFL was performed with immune and
pre-immune sera on HIV-1LAI infected and uninfected Jurkat tat cells
using polyclonal rabbit IgG against HIV-1 gp160 as a positive and
pre-immune mouse sera or PBS as negative controls.
2.6. Inhibition of reverse transcription by sera of DNA-immunized mice
Inhibition of reverse transcription by sera of DNA-immunized mice
was performed using a non-radioactive RT assay kit (Boehringer
Mannheim).
2.7. HIV-1 inhibition
HIV-1 inhibition was performed on HIV-1 laboratory strains LAI
and SF2 with PHA-activated human peripheral blood lymphocytes as
target cells. The inhibiting serum activity was analyzed at 3-fold dilu-
tions starting from 1:10. Inhibition of infection by pre-incubation of
HIV-1 or target cells with immune sera was measured by HIV-1 p24
determination [16]. Inhibition was de¢ned as s 70% reduction of the
p24 viral antigen content in the supernatant as compared to the p24
content in experiments with pre-immune mouse sera.
3. Results and discussion
3.1. Eukaryotic expression of RT
The nucleotide sequence encoding RT of HIV-1 HXB2 [14]
was inserted into an eukaryotic expression vector under the
control of the CMV IE promoter to yield pCMVRT. Eukary-
otic cell lines were transfected with pCMVRT and found to
express a protein with a molecular mass of 66 kDa that re-
acted in Western blotting with rabbit anti-RT IgG where a
strong band was seen (Fig. 1, lane 1). Only weak unspeci¢c
staining was registered for lysates of mock-transfected cells
(Fig. 1, lane 2). Pre-immune rabbit IgG weakly stained lysates
of both transfected and mock-transfected cells (Fig. 1, lanes 3
and 4, respectively).
RT expression was detected by IFL (Fig. 2A). Transfected
cells showed no immunostaining with saline or pre-immune
rabbit IgG (Fig. 2B). Anti-RT IgG did not recognize cells
transfected with empty vector DNA (data not shown). Phase
contrast image of the same ¢elds demonstrated that RT was
expressed preferentially in the cytoplasm.
The protein expressed was enzymatically active. RT activity
was detected in the lysates of pCMVRT-transfected cells as
the ability to extend the (dT)15 primer on a poly(A) template.
The enzymatic activity was registered only if the reaction
mixture for reverse transcription contained less then 10 000
lysed cells. In control experiments, the addition of cell lysate
from mock-transfected cells to recombinant RT led to a 50^
90% inhibition of the RT activity. Inhibition of the RT activ-
ity by the components of a cell lysate is in concordance with
results obtained previously by Lennerstrand et al. [17].
The amount of RT produced assessed by enzymatic activity
was con¢rmed by quantitative indirect ELISA of cell lysates
(data not shown) and estimated to be an average of 0.05^0.15
pg of RT per transfected cell, at 24 and 72 h post transfection,
respectively. Thus, e⁄cient eukaryotic expression of the enzy-
matically active p66 subunit of HIV-1 RT was achieved.
3.2. Immune response induced by the injection of pCMVRT
Expression of RT in pCMVRT-immunized mice lead to
anti-RT antibody production in all animals, as was demon-
strated by indirect IFL, Western blotting and ELISA (Fig. 3).
In a number of pCMVRT-immunized mice, sera did not react
with RT (group 2, A4: Fig. 3) but reacted with RT-derived
synthetic peptides (data not shown). Sera from mice immu-
nized with empty vector DNA did not react with RT in any of
the immunoassays (see, for example, Fig. 3).
In mice injected intra-muscularly, anti-RT antibody titers
ranged between 700 and 10 000, while in mice receiving intra-
epidermal injections, the average titer was markedly lower
reaching only 200. The latter might result from the lower
dose of pCMVRT used, but could also re£ect a di¡erence in
the route of delivery.
Sera collected after the second pCMVRT injection inhibited
up to 70% of the RT activity in vitro (Fig. 4). Inhibition was
exerted by the sera reactive with protein RT as well as by the
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Fig. 1. Expression of RT subunit p66 in pCMVRT-transfected hu-
man DG75 cells. Cells were subjected to 15% SDS-PAGE and elec-
troblotted onto a nitrocellulose membrane. Immunostaining of the
Western blot was performed with rabbit anti-RT IgG, diluted 1:500
(lanes 1, 2) or pre-immune rabbit IgG, diluted 1:100 (lanes 3, 4).
RT DNA-transfected cells (lanes 1, 3), mock-transfected cells (lanes
2, 4). Positions of the molecular mass markers are given to the
right.
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sera reacting with RT-derived peptides only (group 1, A2, B1
and group 2, A4, respectively, Fig. 4). The e¡ect observed in
the presence of normal mouse sera was less than 20% inhib-
ition at a 1:10 dilution (data not shown). Sera from mice
immunized with vector DNA had a certain inhibitory activity,
however the latter was markedly lower than the inhibitory
e¡ect of the sera from pCMVRT-immunized animals (group
3, Fig. 4).
The inhibition of the RT activity by the sera of pCMVRT-
immunized mice could result from induction of antibodies
against regions of RT involved in the enzymatic activity. Re-
active B-cell epitopes were previously localized in the RT re-
gions involved in binding of template and template primer,
catalysis of polymerization, translocation of the template
primer following nucleoside incorporation and RNase H
interaction with DNA [3,4,18].
The nature of the low inhibitory e¡ect exhibited by the sera
of empty vector DNA-immunized mice is unclear. One of the
possible explanations could be induction in the course of
DNA immunization of anti-nucleic acid antibodies [19].
Anti-nucleic acid antibodies could bind primer and/or tem-
plate and thus prevent the e⁄cient reverse transcription.
This possibility has to be further investigated.
Our preliminary experiments demonstrated that sera from
pCMVRT-immunized mice inhibit replication of laboratory
strains of HIV-1 SF2 and LAI (data not shown). Sera of
mice immunized with empty vector DNA also exhibited a
low inhibitory activity if target cells were pre-incubated with
sera prior to HIV-1 challenge. For anti-RT antibodies, virus
inhibition/neutralization might be a result of the ability of
antibodies to enter cells, inhibit the RT activity (as was dem-
onstrated in the in vitro experiments) and thus interfere with
the HIV-1 replication cycle. Intracellular neutralization of vi-
rus by immunoglobulin A antibodies, that are able to form
complexes with newly synthesized viral proteins and thus pre-
vent HIV-1 transmission, was described [20]. The mechanism
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Fig. 2. Detection of RT by IFL of pCMVRT-transfected COS cells. The upper panel shows two ¢elds after staining with rabbit anti-RT IgG
(A) or pre-imune rabbit IgG (B) and FITC-conjugated swine anti-rabbit IgG. The lower panel shows nuclei staining of cells in the same ¢elds
(C).
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of HIV-1 inhibition/neutralization by antibodies induced in
DNA immunization has yet to be understood.
The next step will be assessing the ability of the immune
response against RT expressed in situ to protect mice against
a challenge with HIV-1 pseudotype (amphotropic murine leu-
kemia virus/HIV-1 with expanded cellular and species trop-
ism, [21]). Preliminary experiments demonstrated an up to
60% protection in mice receiving intra-muscular pCMVRT
injections, while no protection was conferred to empty vector
DNA-immunized mice.
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Fig. 3. Titration of anti-RT antibodies in sera of mice immunized with pCMVRT intra-muscularly (group 1, mice A2, B1), intra-epidermally
(group 2, A4) and with vector DNA containing no gene insert intra-muscularly (group 3, A1, A4).
Fig. 4. Inhibition of RT activity by sera of mice immunized with pCMVRT intra-muscularly (group 1, mice A2, B1), intra-epidermally (group
2, A4) and with vector DNA containing no gene insert intra-muscularly (group 3, A1, A4). The data are expressed as relative percentage of in-
hibition compared with the pre-immune mouse serum at a dilution of 640.
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